Correa-Rodriguez, MariaCallejas-Rubio, Jose-LuisRueda-Medina, BlancaRios-Fernandez, RaquelHera-Fernandez, Javier de laOrtego-Centeno, Norberto2023-05-032023-05-032021-11-12Correa-Rodríguez M, Callejas-Rubio JL, Rueda-Medina B, Ríos-Fernández R, Hera-Fernández J, Ortego-Centeno N. Clinical course of Covid-19 in a cohort of patients with Behçet disease. Med Clin (Barc). 2022 Sep 23;159(6):262-267.http://hdl.handle.net/10668/22370The implications of Covid-19 in patients with Behçet's disease (BD) are unknown. Patients with BD usually take long-term therapy with therapeutic agents that have been tested in Covid-19 patients. We aimed to assess the prevalence of Covid-19 in a cohort of patients with BD and investigate whether those patients with a long-term treatment with colchicine, tumor necrosis factor inhibitors (TNFi) or glucocorticoids are at reduced or increased prevalence of Covid-19 related clinical outcomes. A retrospective study was conducted among 244 patients with BD (86.1% females; mean age 43.95±11.11 years). Each participant completed an online questionnaire regarding demographics, medical conditions, dispensed colchicine, TNFi or oral glucocorticoids, Covid-19 infection, clinical symptoms and recovery. The prevalence of Covid-19 infection was 14.75%. Regarding dose of colchicine, the presence of ageusia was lower in patients taking 0.5mg/day of colchicine compared to those taking 1.5mg/day (p=0.021). The prevalence of dyspnea was significantly higher in patients taking TNFi compared with those without therapy (p=0.032). With regards to oral glucocorticoids, no significant differences were found. The prevalence of Covid-19 among patients with BD seems to be higher than that among the general population in Spain. Continuous TNFi therapy might increase the prevalence of worse clinical outcomes such as dyspnea; oral glucocorticoids and colchicine apparently provided no protection against the Covid-19 related clinical outcomes of patients with BD.enBehçet diseaseCOVID-19ColchicinaColchicineCovid-19Enfermedad de BehçetGlucocorticoidesGlucocorticoidsInhibidor del factor de necrosis tumoral alfaTumor necrosis factor alpha inhibitorAdultBehcet SyndromeCOVID-19ColchicineDyspneaFemaleGlucocorticoidsHumansMaleMiddle AgedRetrospective StudiesTumor Necrosis Factor Inhibitorsresearch article35058051open access10.1016/j.medcli.2021.11.0091578-8989PMC8712259https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712259https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712259/pdf